Cubist’s Zerbaxa Challenge Will Be Lack Of Superiority Claim
Executive Summary
The biotech and its acquirer Merck laud the approval of another antibiotic, but its failure to gain superiority in the label puts Zerbaxa at a disadvantage to currently marketed products.